CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial-Reference-Cited by-同舟云学术

CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial

Published:2013-11-22 Issue:1 Volume:143 Page:171-179
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Dezentjé Vincent O.,Gelderblom Hans,Van Schaik Ron H. N.,Vletter-Bogaartz Judith M.,Van der Straaten Tahar,Wessels Judith A. M.,Kranenbarg Elma Meershoek-Klein,Berns Els M.,Seynaeve Caroline,Putter Hein,Van de Velde Cornelis J. H.,Nortier Johan W. R.,Guchelaar Henk-Jan

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-013-2777-6.pdf

Reference31 articles.

1. Stearns V, Ullmer L, Lopez JF, Smith Y, Isaacs C, Hayes D (2002) Hot flushes. Lancet 360:1851–1861

2. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW et al (2005) Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23:9312–9318

3. Rae JM, Sikora MJ, Henry NL, Li L, Kim S, Oesterreich S et al (2009) Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Pharmacogenomics J 9:258–264

4. Cuzick J, Sestak I, Cella D, Fallowfield L (2008) Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol 9:1143–1148. doi: 10.1016/S1470-2045(08)70259-6

5. Mortimer JE, Flatt SW, Parker BA, Gold EB, Wasserman L, Natarajan L et al (2008) Tamoxifen, hot flashes and recurrence in breast cancer. Breast Cancer Res Treat 108:421–426. doi: 10.1007/s10549-007-9612-x

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of HIV on non-adherence for tamoxifen among women with breast cancer in South Africa;Breast Cancer Research and Treatment;2022-12-20

2. Personalizing tamoxifen therapy in adjuvant therapy: a brief summary of the ongoing discussion;Expert Review of Clinical Pharmacology;2022-12-06

3. The frequencies of CYP2D6 alleles and their impact on clinical outcomes of adjuvant tamoxifen therapy in Syrian breast cancer patients;BMC Cancer;2022-10-15

4. The impact of HIV on non-adherence for tamoxifen among women with breast cancer in South Africa;2022-09-12

5. Association of single nucleotide polymorphisms of cytochrome P450 enzymes with experience of vasomotor, vaginal and musculoskeletal symptoms among breast cancer patients: a systematic review;BMC Cancer;2021-05-18